AstraZeneca PLC AZN
This picture changes. Follow AstraZeneca PLC free — email when the signal or risk changes + a Sunday weekly brief.
Follow AstraZeneca PLC freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 4 Aug 2026
General analysis — not personal advice.
HOLD
7/10
Confidence
Current position may be maintained if fundamentals remain unchanged.
Stable growth, strong pipeline and low dilution risk outweigh short-term merger noise and support a neutral signal.
Market sentiment
6/10
→
Trend: Stable
The market retains confidence in the pipeline and management despite short-term uncertainty around merger and regulatory matters.
Price context
The share trades around 157.97 USD after an 8.4 percent decline in the past week and 12.8 percent over the past quarter, indicating that the market has priced in certain risks while underlying fundamentals remain intact.
Risk assessment
4/10
Dilution:
Low
Strong cash flow and profitability
Jurisdiction:
Low
Operations mainly in Western countries
Execution:
Medium
Mixed history on individual studies
About the company
AstraZeneca is a global pharmaceutical company focused on oncology, cardiovascular, renal and metabolic diseases as well as rare diseases. The company develops and markets prescription medicines such as Tagrisso, Imfinzi, Enhertu and Farxiga.
Sector:
Pharmaceuticals
Type:
Biotech
Next report
29 Oct 2026
Q3
Catalysts
Aug 2026
Tozorakimab phase III data
High
Q4 2026
Datopotamab deruxtecan decision
Medium
Q4 2026
Camizestrant PDUFA
High
Horizon:
Bull case
Strong growth in oncology and rare diseases offsets patent expirations and sustains momentum.
Bear case
Merger turbulence with Bristol Myers Squibb and regulatory plus pricing risks create uncertainty.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| Oncology sales | Weaker oncology growth → lower overall revenue growth and margin pressure. | Stronger oncology growth → higher revenues and improved profitability. |
| Regulatory decisions | Delayed or denied approvals → fewer new revenue streams in coming years. | Multiple positive approvals → accelerated pipeline monetization. |
We monitor these factors. Follow the company to get email when any of them hit.
Signal rationale (informational)
Stable growth, strong pipeline and low dilution risk outweigh short-term merger noise and support a neutral signal.
Recent news
- AstraZeneca reported strong Q2 growth of 9 percent but the share fell after news of merger talks with Bristol Myers Squibb. The company reaffirmed its 80 billion USD revenue target for 2030.
Key figures
Revenue
Q2 2026
USD 15.4B
EBITDA
Q2 2026
USD 5.1B
Net income
Q2 2026
USD 2.5B
Cash
Q2 2026
USD 4.9B
Gross margin
Q2 2026
83.6%
Shares outstanding
Q2 2026
1.6B
EPS
Q2 2026
USD 1.62
Price & valuation
Last close
USD 159
Market Cap
USD 246B
1 week
-1.7 %
3 months
-15.4 %
Exchange
LSE
Type
Biotech
Sector
Pharmaceuticals
This picture changes. Follow AstraZeneca PLC free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.